151.22
2.59%
+3.82
After Hours:
151.22
Alnylam Pharmaceuticals Inc stock is currently priced at $151.22, with a 24-hour trading volume of 925.72K.
It has seen a +2.59% increased in the last 24 hours and a +3.07% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $148.5 pivot point. If it approaches the $152.7 resistance level, significant changes may occur.
Previous Close:
$147.40
Open:
$147.15
24h Volume:
925.72K
Market Cap:
$19.13B
Revenue:
$2.00B
Net Income/Loss:
$-332.08M
P/E Ratio:
-36.53
EPS:
-4.14
Net Cash Flow:
$127.82M
1W Performance:
-0.10%
1M Performance:
+3.07%
6M Performance:
-10.50%
1Y Performance:
-20.81%
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Name
Alnylam Pharmaceuticals Inc
Sector
Industry
Phone
617-551-8200
Address
300 Third Street, 3rd Floor, Cambridge, MA
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-16-24 | Downgrade | Goldman | Buy → Neutral |
Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
Oct-11-23 | Downgrade | Oppenheimer | Outperform → Perform |
Sep-29-23 | Initiated | Raymond James | Outperform |
May-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
Apr-26-23 | Initiated | SMBC Nikko | Neutral |
Mar-21-23 | Initiated | Bernstein | Outperform |
Jan-18-23 | Initiated | Canaccord Genuity | Buy |
Sep-09-22 | Resumed | Morgan Stanley | Equal-Weight |
Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
Jun-27-22 | Downgrade | Guggenheim | Buy → Neutral |
Jun-07-22 | Initiated | William Blair | Outperform |
Apr-25-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Mar-01-22 | Initiated | Citigroup | Buy |
Feb-03-22 | Upgrade | Guggenheim | Neutral → Buy |
Jan-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
Nov-22-21 | Upgrade | Goldman | Neutral → Buy |
Nov-22-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Nov-01-21 | Upgrade | Oppenheimer | Perform → Outperform |
Oct-04-21 | Upgrade | UBS | Neutral → Buy |
Aug-04-21 | Downgrade | Piper Sandler | Overweight → Neutral |
Feb-22-21 | Downgrade | Guggenheim | Buy → Neutral |
Feb-12-21 | Downgrade | Citigroup | Buy → Neutral |
Feb-12-21 | Reiterated | H.C. Wainwright | Buy |
Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Sep-30-20 | Resumed | Berenberg | Hold |
Sep-08-20 | Initiated | Citigroup | Buy |
Aug-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
May-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
Apr-24-20 | Resumed | Evercore ISI | Outperform |
Mar-19-20 | Initiated | Berenberg | Buy |
Dec-19-19 | Reiterated | Chardan Capital Markets | Buy |
Nov-20-19 | Initiated | Oppenheimer | Outperform |
Nov-13-19 | Initiated | BofA/Merrill | Buy |
May-23-19 | Resumed | Goldman | Neutral |
Apr-12-19 | Initiated | Evercore ISI | Outperform |
Mar-06-19 | Upgrade | Evercore ISI | In-line → Outperform |
Mar-05-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jan-23-19 | Initiated | UBS | Neutral |
Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
Aug-13-18 | Reiterated | Stifel | Buy |
Aug-07-18 | Upgrade | Stifel | Hold → Buy |
May-04-18 | Reiterated | Stifel | Hold |
Mar-28-18 | Initiated | Evercore ISI | In-line |
View All
Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News
Jump Financial LLC Takes $1.40 Million Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
MarketBeat
Charles Schwab Investment Management Inc. Acquires 19,324 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ ... - MarketBeat
MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stake Reduced by Teacher Retirement System of Texas - Defense World
Defense World
Victory Capital Management Inc. Has $8.76 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Defense World
Defense World
Alnylam (ALNY) Files for Oxlumo Label Expansion in US & EU - Yahoo New Zealand News
Yahoo New Zealand News
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Amalgamated Bank - Defense World
Defense World
Alnylam Pharmaceuticals Inc Stock (ALNY) Financials Data
Alnylam Pharmaceuticals Inc (ALNY) Revenue 2024
ALNY reported a revenue (TTM) of $2.00 billion for the quarter ending March 31, 2024, a +75.20% rise year-over-year.
Alnylam Pharmaceuticals Inc (ALNY) Net Income 2024
ALNY net income (TTM) was -$332.08 million for the quarter ending March 31, 2024, a +68.82% increase year-over-year.
Alnylam Pharmaceuticals Inc (ALNY) Cash Flow 2024
ALNY recorded a free cash flow (TTM) of $127.82 million for the quarter ending March 31, 2024, a +121.14% increase year-over-year.
Alnylam Pharmaceuticals Inc (ALNY) Earnings per Share 2024
ALNY earnings per share (TTM) was -$2.68 for the quarter ending March 31, 2024, a +69.16% growth year-over-year.
About Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia. Its clinical programs also include ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR, which is in the Phase I clinical trial for the treatment of various forms of ATTR amyloidosis; Lumasiran (ALN-GO1) that is in Phase I/II clinical trial for the treatment of primary hyperoxaluria type 1; and Cemdisiran (ALN-CC5), which is in the Phase II clinical trial for the treatment of complement-mediated diseases. The company has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc; and Regeneron Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Cap:
|
Volume (24h):